ONCLIVE NEWS NETWORK: ON LOCATION WILL BE LIVE AT ESMO THIS WEEK - STAY TUNED FOR MORE INFORMATION!

Dr. Saenger on the Need for Immunotherapy Biomarkers

Yvonne M. Saenger, MD
Published: Wednesday, Aug 07, 2013

Yvonne M. Saenger, MD, Assistant Professor in Medicine and Dermatology, Hematology and Medical Oncology, Mount Sinai School of Medicine, discusses the need for biomarkers for immunotherapies.

For a long time, immunotherapies were not effective at all, Saenger says. Now that effective immunotherapies exist, it is important to define which patients are most likely to see benefit. Additionally, it is important to define which patients will not likely see benefit, so that they can receive other treatments or different approaches.

In the case of ipilimumab (Yervoy) for melanoma, only about 5% of patients will see a long term response and 20% are alive at two years. Though the latest data suggest that 40% of patients may be alive at two years, this benefit is still not good enough, Saenger says. The oncology community hopes to develop agents that will help everyone and biomarkers that will help prioritize treatment for those most likely to see benefit.

Yvonne M. Saenger, MD, Assistant Professor in Medicine and Dermatology, Hematology and Medical Oncology, Mount Sinai School of Medicine, discusses the need for biomarkers for immunotherapies.

For a long time, immunotherapies were not effective at all, Saenger says. Now that effective immunotherapies exist, it is important to define which patients are most likely to see benefit. Additionally, it is important to define which patients will not likely see benefit, so that they can receive other treatments or different approaches.

In the case of ipilimumab (Yervoy) for melanoma, only about 5% of patients will see a long term response and 20% are alive at two years. Though the latest data suggest that 40% of patients may be alive at two years, this benefit is still not good enough, Saenger says. The oncology community hopes to develop agents that will help everyone and biomarkers that will help prioritize treatment for those most likely to see benefit.




View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Medical Crossfire®: Evolving Roles for Targeted Melanoma Therapies: Assessing Rapid Progress in the Field and Looking Toward Future CombinationsFeb 28, 20191.5
Community Practice Connections™: New Directions in Advanced Cutaneous Squamous Cell Carcinoma: Emerging Evidence of ImmunotherapyAug 13, 20191.5
Publication Bottom Border
Border Publication
x